Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma

Next Previous
Search
Trial Profile

A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Jun 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sonidegib (Primary)
  • Indications Astrocytoma; Hepatoblastoma; Medulloblastoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis

    • Most Recent Events

    • 01 Mar 2016 Protocol amended as treatment arms changed from 1 to 5 as reported by ClinicalTrials.gov.
    • 25 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 05 Oct 2014 Planned End Date changed from 1 Aug 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top